ARMP:NYE-Armata Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 3.12

Change

0.00 (0.00)%

Market Cap

USD 0.06B

Volume

6.23K

Average Target Price

USD 7.00 (+124.36%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating diseases caused by pseudomonas aeruginosa. The company is headquartered in Marina del Rey, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

N/A

USD161.18B 24.70 2.74
ADPT Adaptive Biotechnologies Corpo..

N/A

USD6.56B 39.50 N/A
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD3.74B N/A N/A
ADCT ADC Therapeutics SA

N/A

USD2.38B -99,999.99 N/A
ZYME Zymeworks Inc

N/A

USD2.06B 300.20 N/A
MYOV Myovant Sciences Ltd

N/A

USD1.87B N/A N/A
RCUS Arcus Biosciences, Inc

N/A

USD1.15B N/A N/A
KDMN Kadmon Holdings, Inc

N/A

USD0.65B 2.20 N/A
CVM CEL-SCI Corporation

N/A

USD0.49B N/A N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90

ETFs Containing ARMP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.00% 38% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.00% 38% F 57% F
Trailing 12 Months  
Capital Gain -14.75% 26% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.75% 26% F 33% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.51% N/A N/A 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.51% N/A N/A 24% F
Risk Return Profile  
Volatility (Standard Deviation) 8.29% N/A N/A 78% C+
Risk Adjusted Return -18.18% N/A N/A 22% F
Market Capitalization 0.06B 28% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.90 87% B+ 38% F
Price / Cash Flow Ratio -3.74 28% F 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -81.61% 57% F 5% F
Return on Invested Capital -165.51% 37% F 1% F
Return on Assets -29.63% 55% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.75 56% F 42% F
Short Percent 0.26% 97% A+ 91% A-
Beta 3.04 7% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector